Background:
Chemotherapy induced peripheral neuropathy (CIPN) is often painful, and is caused by
neurotoxic chemotherapy including vincristine. It is a cause of significant impairment in
quality of life in patients surviving to a solid cancer or malignant lymphoma. The only
recognized prevention is based on pre-existing neuropathy and early detection of neuropathic
signs and symptoms in individuals subjected to neurotoxic chemotherapy, justifying sometimes
a change in the therapeutic strategy when other molecules are available. It seems obvious
that to identify early markers of CIPN and to develop preventive therapeutic strategies, are
priorities for improving patients' quality of life and enable them to follow optimal
treatment.
Purpose:
To describe in patients treated for non-Hodgkin's type B malignant lymphoma with multidrug
therapy containing vincristine, the impact of candesartan on the occurrence of neuropathy
measured by the variation of TNSc (Total Neuropathy Score clinical version, evaluating
clinical signs of neuropathy)